Inactive Instrument
Norda ASA Stock Oslo Bors
Stocks
NORD
NO0010285190
Biotechnology & Medical Research
| Market Cap | 513M 51.7M 45.27M 41.79M 39.02M 73.46M 4.89B 75.14M 503M 194M 2.41B 194M 190M 8.37B | P/E 2023 * |
-
| P/E 2024 | 3.26x |
|---|---|---|---|---|---|
| Enterprise Value | 264M 26.63M 23.32M 21.53M 20.1M 37.84M 2.52B 38.71M 259M 100M 1.24B 100M 97.82M 4.31B | EV / Sales 2023 |
-1.24x | EV / Sales 2024 | 0.4x |
| Free-Float |
6.26% | Yield 2023 * |
-
| Yield 2024 | 32.5% |
| 04-09 | Exercise of Warrants by primary insiders | AQ |
| 10/07/25 | Mandatory Notification of Trade | AQ |
| 04/06/25 | Ocean Sun: Mandatory notification of trade | AQ |
| 27/03/25 | Nykode Therapeutics - Mandatory Notification of Trade by Closely Associated Party of a Primary Insider | AQ |
| 03/03/25 | Notification of trade | AQ |
| 1 day | +3.37% |
| Manager | Title | Age | Since |
|---|---|---|---|
Frode Westvold
CEO | Chief Executive Officer | - | 08/04/2013 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 54 | 31/01/2014 | |
| Director/Board Member | 68 | 20/06/2013 | |
| Director/Board Member | - | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.37% | -6.12% | - | - | 44.67M | ||
| +0.95% | +6.02% | -3.33% | +2.40% | 46.62B | ||
| +5.79% | +16.17% | +421.86% | +634.63% | 40.95B | ||
| +1.12% | +15.18% | +22.74% | -12.71% | 32.26B | ||
| +3.61% | +6.69% | +20.23% | +62.38% | 32.24B | ||
| +8.02% | +6.35% | +17.67% | +34.73% | 25.53B | ||
| +1.13% | +15.66% | - | - | 16.38B | ||
| +1.45% | +17.35% | +72.11% | +127.60% | 15.27B | ||
| +1.06% | +5.79% | +14.20% | +18.67% | 13.61B | ||
| -0.60% | +6.32% | +102.74% | +96.28% | 13.34B | ||
| Average | +2.16% | +11.58% | +83.53% | +120.50% | 26.24B | |
| Weighted average by Cap. | +2.03% | +11.59% | +98.36% | +145.92% |
| 2023 | 2024 | |
|---|---|---|
| Net sales | 86.92M 8.76M 7.67M 7.08M 6.61M 12.44M 828M 12.73M 85.18M 32.88M 408M 32.89M 32.16M 1.42B | 372M 37.46M 32.8M 30.28M 28.28M 53.23M 3.54B 54.44M 364M 141M 1.75B 141M 138M 6.07B |
| Net income | 31.17M 3.14M 2.75M 2.54M 2.37M 4.46M 297M 4.56M 30.55M 11.79M 146M 11.79M 11.54M 509M | 126M 12.69M 11.11M 10.26M 9.58M 18.03M 1.2B 18.44M 123M 47.65M 592M 47.65M 46.61M 2.05B |
| Net Debt | -311M -31.36M -27.46M -25.35M -23.67M -44.56M -2.96B -45.57M -305M -118M -1.46B -118M -115M -5.08B | -249M -25.07M -21.95M -20.26M -18.92M -35.62M -2.37B -36.43M -244M -94.13M -1.17B -94.14M -92.07M -4.06B |
Employees
-
















